Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.
Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, Monti MG, Iaffaioli RV, De Laurentiis M, Ascierto PA, Botti G, De Lorenzo C, Maurea N.
Quagliariello V, et al. Among authors: iaffaioli rv.
Int J Cardiol. 2019 Oct 1;292:171-179. doi: 10.1016/j.ijcard.2019.05.028. Epub 2019 May 17.
Int J Cardiol. 2019.
PMID: 31160077